Arcadia Biosciences (RKDA) Fundamental Analysis: Revenue, Earnings & Valuation

9.53 / 10

Outperform

Fundamental analysis rates RKDA at Outperform with a 9.5/10 score. Bullish drivers include PB‑ROE and Profit‑MV, while Cash‑MV and inventory turnover are weaker. Overall, the company shows solid quality and strong asset‑return metrics.

Analysis Checks(4/10)

Revenue-MV

Value-0.17

Score1/3

Weight-20.93%

1M Return-1.11%

Profit-MV

Value0.41

Score3/3

Weight128.81%

1M Return4.77%

Net income-Revenue

Value0.91

Score1/3

Weight-16.42%

1M Return-0.92%

Quick ratio

Value3.03

Score0/3

Weight-50.30%

1M Return-2.68%

PB-ROE

Value-0.51

Score2/3

Weight40.44%

1M Return2.09%

Rate of return on total assets (%)

Value-11.09

Score2/3

Weight29.45%

1M Return1.32%

Annualized return on total assets (%)

Value-14.78

Score2/3

Weight29.45%

1M Return1.32%

Asset-MV

Value-0.48

Score1/3

Weight-4.35%

1M Return-0.21%

Inventory turnover days

Value133.42

Score1/3

Weight-23.90%

1M Return-1.20%

Cash-MV

Value-0.09

Score1/3

Weight-12.26%

1M Return-0.66%

Is RKDA undervalued or overvalued?

RKDA scores 9.53/10 on fundamentals and holds a Discounted valuation at present. Backed by its -45.14% ROE, -48.15% net margin, -1.29 P/E ratio, 0.73 P/B ratio, and 66.92% earnings growth, these metrics solidify its Outperform investment rating.